Skip to main content
Fuso Pharmaceutical Industries,Ltd. logo

Fuso Pharmaceutical Industries,Ltd. — Investor Relations & Filings

Ticker · 4538 ISIN · JP3823600006 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2022-11-10 Regulatory Filings
Country JP Japan
Listing T 4538

About Fuso Pharmaceutical Industries,Ltd.

https://www.fuso-pharm.co.jp/en/

Fuso Pharmaceutical Industries, Ltd. is a company engaged in the development, manufacture, and sale of pharmaceuticals and medical equipment. The company's core business centers on providing essential medical products, with a primary focus on infusions, such as transfusion fluids, and solutions for artificial kidney dialysis. Its portfolio also includes a wide range of injectables for various therapeutic applications. In addition to supplying prescription drugs to medical institutions, Fuso Pharmaceutical Industries also develops and markets over-the-counter (OTC) medications. The company maintains a commitment to research and development, actively managing a drug pipeline and conducting clinical trials to introduce new treatments.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification confirming the accuracy of the company's quarterly report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like a quarterly report), should be classified as Regulatory Filings (RNS) rather than the report itself. Q2 100
2022-11-10 Japanese
四半期報告書－第100期第2四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Fuso Pharmaceutical Industries, Ltd. with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet, for the second quarter of the 100th fiscal period (ending September 30, 2022). As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2023
2022-11-10 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-8, Paragraph 1. It serves as an officer certification by the CEO and CFO confirming the accuracy of the quarterly report for the first quarter of the 100th fiscal period. Per the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like a quarterly report), should be classified as Regulatory Filings (RNS) rather than the report itself. Q1 100
2022-08-09 Japanese
四半期報告書－第100期第1四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a '四半期報告書' (Quarterly Report) filed with the Kanto Local Finance Bureau in Japan. It covers the first quarter of the 100th fiscal period (April 1, 2022, to June 30, 2022) for Fuso Pharmaceutical Industries, Ltd. It contains detailed financial statements, including the balance sheet and income statement, and management analysis. This fits the definition of an Interim/Quarterly Report (IR). Q1 2023
2022-08-09 Japanese
内部統制報告書－第99期(令和3年4月1日－令和4年3月31日)
Governance Information Classification · 1% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. This type of document is a specific regulatory filing required by Japanese law, which falls under the 'Regulatory Filings' category as it does not fit into the other specific financial report categories like 10-K or IR.
2022-06-29 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. This is a mandatory document in Japan that accompanies the Annual Securities Report (Yukashoken Hokokusho) to confirm the accuracy of the report's contents. Since it is a regulatory filing required by law to accompany the annual report and does not fit into the specific categories of financial reports themselves, it is classified as a Regulatory Filing (RNS). FY 2022
2022-06-29 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.